Frontlight ResearchEarly access
Taking peoplePhase 3
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, double-blind, placebo-controlled, phase 3 trial PEACH 2
Key facts
- Who runs it
- Hospices Civils De Lyon
- Where
- France15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 580 people, planned
- Started
- 10 Nov 2026
- Expected to end
- 1 Mar 2030
- Type of study
- Interventional
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years; Spontaneous (non-traumatic) supratentorial intracerebral haemorrhage diagnosed by brain CT or MRI; Onset of neurologic symptoms within 24 hours; NIHSS score on admission ≤ 25; Informed consent given by the patient or his/her impartial witness; Patients benefiting from a social insurance system or a similar system
Who cannot take part
- Patients who have been part of a clinical study involving another investigational product in the previous 30 days or within 5 half-lives of the other investigational product prior to Screening, whichever is longer, or participant is currently receiving an investigational product
- Previous history of severe depression, or psychotic disorder or suicidal attempt
- Intracerebral haemorrhage known or suspected by study investigator to be secondary to trauma, vascular malformation, haemorrhagic transformation of ischaemic stroke, or cerebral tumour
- Patients with inaugural seizures at the onset of symptoms associated with intracerebral hemorrhage
- Current use of antiseizure drugs or history of epilepsy
- Known terminal illness; Known allergy or hypersensitivity to Levetiracetam or other pyrrolidone derivatives, or any of the excipients; Known allergy or hypersensitivity to microcrystalline cellulose or lactose; Being under legal protection
- Patients with QTc prolongation
- Severe renal insufficiency (creatinine clearance < 30 ml/min)
- Patients taking probenecid, methotrexate or macrogol
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
to establish if primary prophylactic antiseizure drug improves functional outcome at 6 months in patients with ICH.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 6 November 2026